Skip to content
Menu

Piloto

1263 posts

Posts (1263)

Piloto BABA 5 years ago #1161

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Piloto TSLA 5 years ago #1162

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Piloto BABA 5 years ago #1163

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Piloto VXRT 5 years ago #1164

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Piloto SNDL 5 years ago #1165

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Piloto SNDL 5 years ago #1166

Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021

Read more at:
https://thefly.com/n.php?id=3238123

Piloto BABA 5 years ago #1167

Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021

Read more at:
https://thefly.com/n.php?id=3238123

Piloto RIOT 5 years ago #1168

Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021

Read more at:
https://thefly.com/n.php?id=3238123

Piloto MRNA 5 years ago #1169

Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021

Read more at:
https://thefly.com/n.php?id=3238123

Piloto MARA 5 years ago #1170

Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021

Read more at:
https://thefly.com/n.php?id=3238123